Keywords: ligand, planning, ph, ii, targretin, trials, new
Ligand Planning Ph II Targretin Trials
Article | 12 February 1998
New preclinical data showing that Ligand's retinoid X receptoragonist, Targretin (LGD 1069), can regress 72% of breast tumors in an animal model ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
